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What is the SmartPill®?
Christina Ciccone, fourth-year pharmacy student from Pickerington, Ohio; Pul Lee, fourth-year pharmacy student from
Seoul, South Korea; Kimberly Loughlin, fifth-year pharmacy student from Mishawaka, Ind.; David Koh, PharmD, assistant
professor of pharmacology
Abstract
The SmartPill® is a new, noninvasive technology to evaluate
the gastrointestinal tract. It is a nondigestible capsule that
migrates through the gastrointestinal tract to measure pH,
pressure, and temperature. It was approved by the FDA in
2006 for the evaluation of colonic transit time in patients
with chronic constipation and to evaluate gastric transit time
in patients with suspected gastroparesis. Other currently
used gastrointestinal monitoring systems have some disadvantages, and the SmartPill® is suggested as an alternative.
The SmartPill® has also been used for research purposes in
various studies and has the potential to be used in diagnosis
and monitoring of other gastrointestinal diseases. The aim of
this article is to evaluate the clinical significance of the
SmartPill® by comparing it to other previous gastrointestinal
monitoring methods, examining the FDA approved indications, assessing other possible uses for it and providing
health care professionals with key counseling points for patients.
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Introduction
The SmartPill®, or wireless motility capsule (WMC), is a relatively new, noninvasive gastrointestinal (GI) monitoring device.1 It comes in the form of a capsule and can be used to
measure pressure, pH and temperature in the GI tract. Once
it is ingested, the WMC monitors conditions in the GI tract as
it travels through the body until it is excreted naturally in the
feces.2 The WMC was developed by the SmartPill® Corporation based in Buffalo, New York, and successfully received
U.S. Food and Drug Administration (FDA) approval in 2006
to market in the United States.3 When funds to cover the production and development costs were exhausted, the
SmartPill® Corporation was sold to Given Imaging, an Israeli
company that develops similar devices, through which the
SmartPill® is currently made available. 4
Why should pharmacists be familiar with the WMC?
• The WMC has various applications for research on
the effect that drugs and disease states can have on
GI motility.
• Patients and doctors may approach pharmacists
with questions about the WMC.
• It is important to understand new monitoring methods so that they can be compared to current methods in order to recommend the best procedure for
patients.
• To help improve the care of patients.
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This article will highlight the important aspects of the WMC
and compare it to several other GI monitoring methods available. Current FDA indications of WMC will also be examined,
as well as the applications for research and potential future
uses. Finally, important counseling points for pharmacists
regarding the WMC will be reviewed.
About the SmartPill®
The WMC is a nondigestible, disposable capsule.1 Its size is
26 mm by 13 mm, which is slightly larger than a multivitamin tablet. It contains sensors that measure pH, pressure and
temperature as it travels through the GI tract. The range of
the pH sensor is 0.5 to 9.0 (accurate to ± 0.5), the pressure
range is 0 to 350 mmHg (accurate to ± 5 mmHg), and the
temperature range is 25 to 49°C (accurate to± 1°C).5
The capsule uses amplitude-shift keying (ASK) modulated
radio frequency signals of 434 MHz to transmit the data gathered from these sensors to a portable receiver (sized 14 cm
by 11 cm by 3 cm).S,6 The receiver is worn on either a belt
clip or lanyard by the patient throughout the procedure.1
After the test, the receiver is connected to a docking station
that downloads the data onto a computer with MotiliGITM
Software. The program analyzes the results and converts
them into a printable report.6,7
Specifically, the WMC can measure and differentiate between
gastric emptying time (GET), small bowel transit time
(SBTT), combined small and large bowel transit time
(SLBTT), colonic transit time (CTT) and whole gut transit
time (WGTT).6 Figure 1 shows a sample of the data obtained
from the WMC and its interpretation of GI transit times.a
Cassilly and colleagues determined the WMC usually empties
from the stomach during phase III migrating motor complexes (MMC) that follow the end of the fed state by comparing it
with data from gastric emptying scintigraphy (GES) and antroduodenal manometry.9 This confirmed that the WMC
mimics the emptying pattern of nondigestible solids, rather
than digestible foods. Other studies found varying levels of
correlation, so the mechanism needs further studies to be
fully understood.
The WMC is primarily used in the setting of a clinic or physician's office as a GI motility monitoring test to diagnose
motility disorders, such as gastroparesis (determined by delayed GET) and chronic constipation (using CTT or SLBTT as
a surrogate in cases of undetermined CTT).1,6 Usually, the
WMC test is prescribed when the patient is experiencing unexplained GI symptoms including nausea, bloating, constipation, abdominal pain and/or vomiting.1 By measuring GI
transit times, it is possible to more accurately diagnose and
treat the disease and thus eliminate much trial and error.
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One limitation of the WMC is its relatively large size, which
makes it difficult to swallow, as well as the possibility that it
can be temporarily wedged in the stomach, leading to prolonged GET and WGTT.lO Other limitations include the fact
that the receiver must be kept in close proximity throughout
the procedure and the limited battery life. Also, if the capsule
exit cannot be confirmed due to technical issues of the receiver, in which case an X-ray is required, this will add extra
costs and difficulty for the patient. These issues must be
carefully considered before deciding on the best option for
the patient.
How to use the SmartPill®
Given Imaging has a patient education pamphlet that instructs patients on how to prepare for the test and about the
administration of the WMc.2 Eight hours before the test, patients are instructed not to eat or drink anything except water. This is unlikely to be an issue since the WMC is usually
administered in the morning, so the fasting prior to the test
is simply overnight.

Gastroen terology
When the patient arrives at the clinic or the physician's office
for the appointment (which typically lasts only 30 minutes),
they are given a SmartBar® to eat before swallowing the capsule.2 The SmartBar® is a standardized nutrient bar containing 66 percent carbohydrates, 17 percent protein, 2 percent
fat and 3 percent fiber.11 It stimulates the post-prandial state
of the stomach so that each patient has a consistent starting
point for the administration of the WMC to allow an accurate
measurement of GI transit times.2 Once the patient has eaten
the SmartBar®, the physician activates the WMC by placing it
on the activation fixture. 1 2 The WMC is then ingested and the
patient is given the receiver that records the data from the
capsule. 2 At this point the patient is free to leave and resume
their normal daily activities as long as they fast for six hours
after the administration of the WMC and wear the receiver.
Even when sleeping or bathing, the receiver should be kept
no more than a few feet away from the patient to allow for
complete data collection.
The test lasts about three to five days or as long as it takes
for the WMC to be excreted.2 If not excreted within five days,

Figure 1. Sample Data From a Wireless Motility Capsule.

Sample of pH, temperature and pressure data collected by the wireless motility capsule (WMC) and the three main transit times that can be
determined by its utilization: gastric emptying time, small bowel transit time and colonic transit time.a Upon ingestion, WMC detects temperature increase to body temperature. The GET is determined by the abrupt rise in pH ~ 2, which signals the WMC's exit from the acidic
stomach into the basic intestine. The SBTT is measured as the time period from GET to a second major pH change (abrupt drop ~ 1 pH
units), which represents WMC exit from the ileum and entrance into the relatively more acidic cecum. The CTT is the time from WMC entry
into the cecum to its excretion from the body, detected by an abrupt and sustained temperature drop. Used with permission
from: Saad RJ, Hasler WL. A technical review and clinical assessment of the wireless motility capsule. Gastroenterol Hepatol (N Y). 2011;7
(12) :795-804.
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the battery life of the capsule/receiver set may expire, resulting in incomplete data collection. Patients should allow bowel movements to remain in the toilet for five minutes to allow
the capsule to detect the temperature change once it has
been excreted, which will trigger the indicator light on the
receiver.to After one week, if neither the receiver nor the patient can confirm the passage of the capsule, the patient may
have to undergo an abdominal X-ray to ensure excretion.11
Once data collection is finished, the patient returns the receiver to the physician's office where the results can be
downloaded and analyzed.2 It is not necessary for the patient
to retrieve the capsule.

Comparison with Other Methods
Scintigraphy
Scintigraphy and radiopaque markers have commonly been
used to evaluate whole gut transit.13 Whole gut transit scintigraphy (WGTS) involves a three to four day test. Patients
are required to stop medications that may have effects on GI
motility for 48 hours before the test. Patients then ingest two
large scrambled eggs labeled with 500µCi of 99m-Tc sulfur
colloid served between two pieces of toasted white bread,
and 300ml of water containing 125µCi of 111-In-DTPA. The
data is obtained by a large field of view camera with a medium energy collimator and a nuclear medicine computer.14
Although scintigraphy involves minimal exposure to radiation and is able to assess whole gut transit, it is expensive
and has a long duration of time to study, making it unsuitable
for practice. A study by Maqbool and colleagues suggested
that the WMC can be the next improved method for assessing
GI motility. The study compared the whole gut transit of 10
healthy subjects using scintigraphy and the WMC simultaneously, and the transit time between the two methods was
strongly correlated, indicating that the WMC gives comparable results to scintigraphy.13 Furthermore, a study by Cassilly
and colleagues also observed the strong correlation between
scintigraphy and the WMC for measuring GET. Their experiments were conducted with 15 normal subjects receiving
antroduodenal manometry, scintigraphy, and the WMC. 9 Because the WMC is convenient and requires less work by an
administrator as compared to scintigraphy, it may represent
a superior choice as an examination tool due to its similar
level of accuracy.13
Antroduodenal Manometry
The migrating motor complex (MMC) is one of the most studied and well-known patterns of GI motor function to detect
various GI disorders, such as irritable bowel syndrome, functional dyspepsia, gastroparesis and constipation.is Phase III
MMC in the stomach and small intestine has been a challenging region to evaluate, and the standard method of antroduodenal manometry is invasive in nature. The instrument
requires cleaning out of the intestinal tract to insert the
water perfused or solid state catheter to measure the intraluminaI pressure.16,1 7 In contrast, the WMC's noninvasive characteristic can be an alternative method to detect phase III
MMC. A study from Brun and colleagues conducted a comparative analysis of phase III MM Cs in the stomach and small
bowel by administering the WMC and antroduodenal manometry concurrently to 18 patients. The outcomes of the
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study revealed that the WMC was able to detect with good
precision the phase III MMC, which was identified as high
amplitude contractions. In the study, the researchers stated
that the WM C's characteristic of freely floating inside the gut
might have resulted in differences in luminal pressures, requiring different parameters for interpretation. However,
this limitation of needing a new set of interpretation tools
can outweigh the benefits for the noninvasive nature of the
WMC when compared to the standard test of the antroduodenal manometry. 1s Additionally, antroduodenal manometry
has disadvantages not shared with the WMC. A study by Hasler and colleagues indicated that cleansing the colon with a
lavage solution to perform antroduodenal manometry might
disrupt physiological conditions of fecal retention, which
lead to inaccurate assessment in constipation studies. Furthermore, manometry requires specialized equipment and
manpower, making it a challenge to use frequently in a clinical setting.17 The WMC technology has shown its potential in
the Brun and colleagues study to extend from its FDA indicated uses in the diagnosis of constipation and gastroparesis to
accurately detect phase III MMC.

Radiopaque Markers
Even though radiopaque markers (ROMs) have been used
traditionally to measure CTT, this technique requires radiation, and its lack of standardization and compliances makes it
a technique that some health care professionals are reluctant
to use. The ROMs are plastic beads or rings that are packaged
in a capsule, and a single capsule technique or a multiple capsules technique is used to obtain the data.is The single capsule technique is when the patient ingests a single capsule
followed by several abdominal X-rays until all markers are
excreted, or a single abdominal X-ray is taken on day 5.
Because this method is time-consuming and the patient is
exposed to high levels of radiation, the multiple capsules
technique is preferred, where the patient ingests one capsule
a day for three days, and abdominal X-rays are taken on day
4 and day 7 or only on day 7.
A ROM test is not capable of analyzing regional gut transit,

and performing the test sometimes requires multiple visits.19
In order to suggest an alternative method to monitor CTT, a
study by Rao and colleagues utilized the WMC and ROM to
compare CTT, WGTT, SBTT and GET between 78 constipated
patients and 87 healthy control patients for five days. The
study was designed to assess the ability of the WMC to differentiate between CTT and WGTT and distinguish normal and
slow CTT. Furthermore, the study compared the accuracy of
the information with that of the ROM method. The study observed a delay in GET, CTT and WGTT with constipation patients. The diagnostic accuracy to determine constipation
exhibited specificity of 0.95 and reasonable sensitivity of
0.46 with the WMC, and 0.95 specificity and 0.40 reasonable
sensitivity for ROM, which demonstrated a great congruency
between these two tests. Additionally, the high specificity
indicated the WMC's ability to distinguish between normal
and slow CTT, and its continuous and more direct measure of
CTT may be able to indicate the severity of slow transit constipation in the future. Because the WMC does not require
radiation and has results agreeable with ROM, it has demon-
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strated its potential to be a comparable measurement method for CTT and become a standardized technique.

SmartPill® Uses
The WMC was approved as a GI motility monitoring device in
2006 according to the FDA 510K statement, having met all
the clinical testing and safety criteria for such devices.3 It is
used mainly to diagnose gastroparesis, but it can also be used
to diagnose chronic constipation. Off-label uses include research analyzing how certain diseases and drugs affect GI
motility and conditions. The WMC also has the potential to be
utilized to diagnose diseases involving hypersecretion of acid.20
Approved Indications
Gastroparesis
Gastroparesis is a chronic GI disorder in which the emptying
of the stomach is delayed for reasons other than a physical
obstruction.s Patients may experience nausea, vomiting,
bloating, abdominal pain and dyspepsia. Due to the fact that
these symptoms are common to many GI disorders, it can be
difficult to pinpoint the exact cause based only on the clinical
presentation. A prospective, multicenter study by Kuo and
colleagues examined the ability of GET measured by the
WMC to differentiate between healthy and gastroparetic subjects compared to GES.
The study involved 87 healthy subjects and 61 subjects with
gastroparesis.s All patients were simultaneously given the
WMC to assess GET and a [99mTc]-SC radiolabelled meal to
measure percent of meal retained at 30 minute intervals by
GES. The WMC was taken first, followed by the completion of
the radiolabelled meal within 20 minutes of capsule ingestion. A correlation greater than 0.7 was considered to be significant. Results found GET (measured in minutes), GES-2h,
and GES-4h (measured in percent of meal retained in the
stomach) to be significantly different in healthy subjects as
compared to gastroparetic subjects (p-value <0.05). The GET
was most strongly correlated with GES-4h (0.73), which was
greater than the target 0. 7 for significance. The correlation
between GET and GES-2h did not reach statistical significance (0.63). Both GET and GES-4h were shown to be clinically useful for diagnosing gastroparesis, so the WMC could
be considered a viable replacement for GES.

Chronic Constipation
There is little known about colonic motility in normal, constipation, and constipation-predominant irritable bowel
syndrome (C-JBS). The study from Hasler and colleagues conducted an experiment to characterize regional differences in
colon pressure, relate motor differences in constipation to
colon transit and quantify the role of irritable bowel syndrome (JBS) in altered contractility with constipation using
the WMC.17 Because the capsule continuously measures luminal pH, pressure and temperature, it was used to obtain a
greater understanding of the relationship between colon motor activity and constipation, as well as to differentiate C-JBS
from constipation not related to !BS. The study recruited 53
healthy and 36 constipated subjects. Twelve of the constipated participants had C-JBS, and 24 had functional constipaSummer 2015 Volume 6, Issue 3
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tion. The study concluded that colon pressure activity is
active distally, rather than proximally, in the control group.
Due to JBS, constipated patients with normal or moderate
slow transit demonstrated an increase in motor activity,
which showed differences in transit and motility among different subtypes of constipated patients.
The study discussed some limitations of WMC technology.17
First, the capsule has one pressure sensor, which did not allow it to distinguish between mixing and propulsive motility,
identify high-amplitude propagating contractions or differentiate motor artifact from luminal contractions. Second, due
to the capsule's size larger than stool, the capsule was not
managed physiologically in the body. Some studies have observed that the WMC moved faster in the colon than small
particles or liquids. Finally, it is difficult to detect the position
of the capsule accurately, except when the capsule was in
ileocecal transit and before excretion. Despite its weaknesses, the WMC may have potential future use in testing responsiveness to laxatives in different patients. Also, it can be a
useful method to decide treatment options for difficult constipation cases.

Research Purposes
Spinal Cord Injury
Patients who have experienced spinal cord injury (SCI)
sometimes experience a disruption in their GI fimction.21 It
can be difficult to monitor and research their condition with
traditional testing methods due to the invasive nature of existing tests or necessity to alter lifestyle during the testing
period, both of which can potentially affect results. Williams
and colleagues studied the effects of SCI on GET, CTT and
WGTT using the WMC as their GI motility monitoring device.
Their goal was to determine if the WMC was a viable option
for monitoring SCI patients and evaluate their GI function.
The study enrolled 20 SCI patients and 10 healthy subjects.21
The SCI patients had complete or incomplete paraplegia and
tetraplegia for more than six months as well as abnormal
bowel movements. The SCI group had prolonged GI transit
times (GET: 10.6 ± 7.2 hours, CTT: 52.3 ± 42.9 hours, WGTT:
3.3 ± 2.5 days) compared to the healthy patients (GET: 3.5 ±
1.0 hours, CTT: 14.2 ± 7.6 hours, WGTT: 1.0 ± 0.7 days) with
p-value less than or equal to 0.01. These results supported
evidence from previous studies that used more invasive
methods that indicated SCI patients had delayed GI transit
times. None of the subjects had difficulty swallowing the
WMC, and they reported no complications or side effects as a
result of taking the WMC. The study concluded that the WMC
was most likely a safe and effective method for GI monitoring
in patients with SCI.

Medications
Certain drugs can have an impact on GI motility. Rozov-Ung
and colleagues performed a crossover study to test the ability of the WMC to evaluate the effect of erythromycin IV 150
mg versus morphine IV 0.05 mg/kg versus normal saline IV
on GET and motor activity.11 Erythromycin is well known to
decrease GET while morphine increases GET.
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The study included 15 healthy adults who were administered
each course of therapy, in random order, on three separate
occasions at least one week apart.11 The GET for erythromycin was significantly faster than saline (p-value < 0.001),
while GET for morphine was somewhat slower compared to
saline (p-value = 0.11 ). Contractility was not significantly
different when comparing morphine to erythromycin
(p-value =0.14) or saline (p-value =0.12). The WMC successfully detected expected changes in GI motility caused by
erythromycin and morphine, and thus may be a valuable tool
for researching the effects of other drugs on GI motility.
Dietary Fiber
Dietary fiber is well known to affect GI motility, but for many
years the only methods to quantify the effect were either
invasive or involved radiolabeled food.10 Timm and colleagues performed a controlled, crossover trial to determine
whether the WMC could measure the difference in GI transit
times between a wheat bran and a low fiber control diet.
Ten healthy subjects were enrolled in the study.10 Each subject completed both dietary interventions. These interventions involved eating either the control or the wheat bran
cereal three days prior to each of their visits and keeping a
food diary. The results showed that the wheat bran intervention caused a significant decrease in CTT and WGTT, in which
they observed a mean difference of -10.8 (p-value = 0.006)
and -8.9 (p-value = 0.02), respectively. The GET and SBTT
were not significantly different between the two interventions. The WMC was therefore able to detect differences in
GI motility related to dietary interventions and thus demonstrated its potential for use in future digestive studies.

Appetite
Willis and colleagues designed a randomized crossover study
to evaluate the utility of the WMC in research involving GI
transit times and also to determine if GET had any relation to
appetite.7 The trial compared GET, as measured by the WMC,
to appetite, as determined by visual analog scales (VAS) after
two different types of meals. These meals were of equivalent
caloric and dietary fiber content, but one was a liquid meal
and the other a solid meal.
Fourteen women were randomized according to which
intervention they would receive first: the liquid breakfast
consisting of fruit juice and skim milk or the solid breakfast
of oatmeal, blueberries and apples.7 The GET was longer with
the solid breakfast than the liquid breakfast: 4.2 ± 0.2 hours
versus 3.3 ± 0.2 hours, respectively (p = 0.003). Analysis of
appetite using VAS showed that patients were less hungry
and more satisfied after the solid meal. Thus, there was a
negative correlation between GET and appetite. The study
concluded that WMC was a reasonable option for assessing
GET in a nutrition or appetite study, particularly because the
free mobility of the patient using WMC was as "true-to-life"
as possible. One of the limitations of the WMC is the fact that
the capsule is large and nondigestible, so it does not empty
from the stomach until after the smaller, particulate food
matter.
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Critically Ill Trauma Patients
It is widely known that critically ill patients have difficulty
with gastric emptying due to insufficient nutrition and
delayed digestive function.22 However, monitoring the GI
malfunction of these patients is difficult when they are mechanically ventilated. Furthermore, monitoring the small
bowel is especially difficult due to its length, location and
twisted shape. The WMC has been introduced as an alternative and innovative technique to assess GI motility in critical
care patients. The study by Rauch and colleagues compared
GET, SBTT and WGTT in eight critically ill trauma patients
with 87 healthy volunteers from different trials using the
WMC. This prospective cohort study demonstrated that the
GET and the SBTT were significantly delayed for the critically
ill patients group. Also, the trauma patients required 10 days
to process the capsules, as compared to 1.2 days with the
control group.
The results correlate with other studies that measure
delayed gastric empty time with other techniques such as
scintigraphy, C-octanoic acid breath test and antroduodenal
manometry.22 The WMC demonstrated its ability to become
an alternative method to other invasive techniques to monitor critically ill patients' gastric function, including the small
intestine, where traditional technology cannot detect well.

Cystic Fibrosis
Regulating specific pH ranges in the GI tract is important to
digest foods and protect from ingested microorganisms.23
Patients with cystic fibrosis (CF) are characterized by a mutation in the cystic fibrosis transmembrane conductance regulator protein (CFTR) in the pancreas and other organs. This
leads to insufficient neutralization of the gastric acid in the
duodenum, causing inadequate nutrient absorption and failure to activate enteric-coated pancreatic enzyme replacement
therapy (PERT) for patients with pancreatic insufficiency (Pl).
An antimony sensor in a swallowed pill device was used in
some older studies to show that CF patients experience a
more acidic small intestine relative to controls. This device is
no longer used due to its instability, and a recent study by
Gelfond and colleagues utilized the WMC to evaluate its potential uses to provide a distinct pH profile in CF patients. The
study found that there was a statistically significant difference
between mean pH values during the first 23 minutes of small
bowel transit. Cystic fibrosis patients have shown a prolonged
time interval to reach and maintain pH 5.5 and pH 6.0, which
are pH ranges crucial for PERT dissolution. Accordingly, CF
patients experienced an inadequate neutralization of gastric
acid in the duodenum. Moreover, patients with CF took significantly longer time in the SBTT, while GET, CTT and WGTT
were not significantly different between the two groups.
This study demonstrated the ability of the technology in the
WMC to provide the distinct gastrointestinal pH profile in CF
patients, which may give a valuable understanding in optimizing nutritional and pharmacological interventions in the
future.23 For instance, the research excluded CF patients
without acid suppression, but there are some studies that
have shown that inhibiting gastric acid may have an effect on
respiratory disease by eliminating bacterial properties of
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gastric acid, and the WMC can be applied to examine the effects of acid suppression in patients with CF. Furthermore,
the WMC can be a useful tool to evaluate new classes of CFTR
modulating drugs as well as a pharmacological intervention
tool for CF patients to individualize treatments according to
their gastrointestinal pH profile.
Potential Future Uses
Gastroesophageal Reflux Disease (GERO)
Although the WMC is not currently approved to diagnose
GERO, it is well-equipped to measure gastric acid output
(GAO), which is often a key component of GERD and other
gastric hypersecretory diseases.20 Weinstein and colleagues
evaluated the use of the WM C as a noninvasive alternative to
measuring GAO compared to a riasogastric tube. They found
the WMC was an accurate and viable method of measuring
GAO in healthy patients, and therefore had potential for use
in research and management of disorders involving gastric
acid secretion such as GERD, Barrett's esophagus, ZollingerEllison syndrome and atrophic gastritis. They also thought it
might be applicable to antisecretory drug development and
gastric cancer screening.
The WMC and nasogastric tubing were both used to determine the GAO in 20 healthy subjects.20 Additionally, 12 of the
subjects were later given a second WMC to test reproducibility. The statistical analysis predetermined a range (r) of 0.5
to 0. 7 to be considered an acceptable correlation. Results
showed a strong correlation between GAO as measured by
the WMC, compared to conventional measurements, such as
basal acid output (BAO) (r = 0.51, p-value = 0.02), maximal
acid output (MAO) (r = 0.72, p-value = 0.0004) and peak acid
output (PAO) (r = 0.60, p-value = 0.006). The only limitations
of this study were the small sample size and the rapid GET in
some patients causing an overestimation of GAO.
Patient Counseling
Pharmacists should counsel patients on important points
about the function and use of the WMC. Additionally, pharmacists should warn patients to check with their physician
about medications they are using that might hinder accurate
test results or disease states in which WMC might be contraindicated.2 Medications that might affect the procedure
include pain medications, sedatives, tranquilizers, antispasmodics, promotility agents and even medications taken for
heart disease, hypertension or diabetes. Pharmacists should
advise the patient to complete a medication history review
with their physician prior to undertaking the test. The main
condition in which the use of WMC is not recommended is in
patients with GI obstruction. Severe obesity may also interfere with data collection and may not be effective for these
patients. The WMC procedure should not be used in patients
under age 18 years.
It is important to advise patients and physicians about the
cost of the WMC procedure. A capsule alone costs $600 and
the startup cost for the entire system is more.lo As of 2013,
the WMC was assigned a reimbursement Category 1 CPT
code (91112), stating that the 2013 National Average Medicare Physician Fee was set at $1,188.93.2 4 This means that
Summer 2015 Volume 6, Issue 3
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Medicare and some other insurance companies will cover the
physician's fee for the procedure, but the patient will likely
still have to pay for the cost of the equipment. If cost is likely
to be a barrier for the patient, the WMC may not be the best
option.
Conclusion
The WMC has proven to be as effective as other GI monitoring methods such as scintigraphy, antroduodenal manometry
and ROM for diagnosis of gastroparesis and chronic constipation as well as a variety of research purposes. It also seems to
have the potential for monitoring and management of hypersecretory conditions such as GERD. Both the advantages and
limitations of the WMC in comparison to other methods need
to be taken into consideration when deciding the best course
of action for the patient. However, the WMC seems to be a
valid option in many situations.
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